Background and objective: No published studies have examined the long-term effects of non-invasive ventilation (NIV) in cystic fibrosis (CF). Our primary aim was to determine if adults with CF and sleep desaturation were less likely to develop hypercapnia with NIV AE O 2 compared to low-flow oxygen therapy (LFO 2 ) or meet the criteria for failure of therapy over 12 months. We studied event-free survival, hospitalizations, lung function, arterial blood gases (ABG), sleep quality and health-related quality of life. Methods: A prospective, randomized, parallel group study in adult patients with CF and sleep desaturation was conducted, comparing 12 months of NIV AE O 2 to LFO 2 . Event-free survival was defined as participants without events. Events included: failure of therapy with PaCO 2 > 60 mm Hg, or increase in PaCO 2 > 10 mm Hg from baseline, increases in TcCO 2 > 10 mm Hg, lung transplantation or death. Outcomes were measured at baseline, 3, 6 and 12 months, including lung function, ABG, Pittsburgh Sleep Quality Inventory (PSQI), SF36 and hospitalizations. Results: A total of 29 patients were randomized to NIV AE O 2 (n = 14) or LFO 2 (n = 15) therapy for 12 months. Of the 29 patients, 18 met the criteria for event-free survival over 12 months. NIV AE O 2 group had 33% (95% CI: 5-58%) and 46% (95% CI: 10-68%) more event-free survival at 3 and 12 months than LFO 2 group. No statistically significant differences were seen in spirometry, ABG, questionnaires or hospitalizations. Conclusion: NIV AE O 2 during sleep increases event-free survival over 12 months in adults with CF. Further studies are required to determine which subgroups benefit the most from NIV.
INTRODUCTION
Patients with cystic fibrosis (CF) and advanced lung disease are known to develop hypoxaemia and hypercapnia during sleep, [1] [2] [3] [4] where hypoventilation during sleep usually predates daytime hypercapnia. Hypoxaemia and hypercapnia portend poor prognosis and remain indications for lung transplantation. 5 Therefore, the prevention of respiratory failure during sleep in CF may prolong survival. Long-term oxygen therapy has not been shown to improve survival in people with CF. 6 A Cochrane review of the use noninvasive ventilation (NIV) in CF concluded that NIV in combination with oxygen therapy improves gas exchange during sleep to a greater extent than oxygen therapy alone in people with moderate to severe CF lung disease in single night studies. 7 Uncontrolled, non-randomized studies suggest survival benefit with NIV in addition to being an effective bridge to transplantation. [8] [9] [10] [11] [12] Previous studies have demonstrated NIV as superior to low-flow oxygen therapy (LFO 2 ) in improving sleep hypoventilation, 3 ,13 yet short-term nocturnal NIV has not been shown to reduce daytime PaCO 2 in patients with CF with daytime hypercapnia. 13 No studies have been published that examine the longterm effects of NIV in CF.
The primary aim of this study was to determine if patients with CF and documented sleep oxyhaemoglobin desaturation were less likely to develop hypercapnia and therefore show a survival (no death or transplant) benefit, if treated with NIV AE O 2 compared to LFO 2 , and were less likely to meet the criteria for failure of therapy. Secondary aims were to examine the effect of the above-mentioned interventions on hospitalizations, lung function, arterial blood gases (ABG), sleep quality and health-related quality of life (HRQoL).
METHODS

Study design
A prospective, randomized, parallel group study in adults with CF and sleep oxyhaemoglobin desaturation was conducted. Patients were recruited from two large Australian adult CF centres (Royal Prince Alfred Hospital (RPAH), Sydney, and The Prince Charles Hospital (TPCH), Brisbane). Patients were randomized to receive either 12 months of NIV AE O 2 (experimental) or LFO 2 (control) during sleep. Intervention order was determined by computer-generated block randomization (blocks of 4, stored in sealed, sequentially numbered opaque envelopes), performed by an independent person not involved in the interventions. Researchers were blinded to block size. Outcomes were measured at baseline and then at 3, 6 and 12 months by an assessor not blinded to group allocation. Research ethics approvals were obtained through RPAH and TPCH Human Ethics Review Committees (RPAH protocol numbers X97-0204/X01-0200/ X06-0015/X10-0124, 1998-2015 and PCH -EC2275). Written, informed consent was obtained from all patients.
Study participants
Participants were eligible for the study if they: were clinically stable 14 ; had a total sleep time (TST) minimum average oxygen saturation (SpO 2 ) < 90% (the mean of the minimum SpO 2 in every 30 s epoch of sleep) during a diagnostic sleep study on room air; agreed to receive either NIV by mask or oxygen therapy for 12 months; and were able to sign informed consent. Diagnostic sleep studies were performed as routine care and in several patients as part of a lung transplant assessment protocol or whilst participating in another study. 15 Patients were excluded if they had: hypercapnic respiratory failure (PaCO 2 > 60 mm Hg); had severe coexisting disease such as HIV, malignancy, end-stage liver disease, persistent pneumothorax and Burkolderia cepacia complex infection; or had recent psychological or psychiatric problems likely to impair ability to participate. Being on previous LFO 2 or short-term NIV did not exclude participation.
Intervention
The experimental group (NIV AE O 2 ) had acclimatization to NIV (VPAP device, ResMed, Bella Vista, NSW, Australia) for at least several hours until the patient felt able to sleep on therapy. Mask choice was individualized and based on comfort and seal, with both nasal and fullface masks selected. A second sleep study was performed where NIV pressures and requirement for oxygen was titrated aiming to maintain SpO 2 ≥ 90% during all sleep stages and to prevent CO 2 retention. Expiratory positive airway pressure (EPAP) was titrated with the aim of abolishing snoring and obstructive events, and inspiratory positive airway pressure (IPAP) was titrated to prevent rises in transcutaneous carbon dioxide (TcCO 2 ) and prevent hypopnoeas. Oxygen was added when the abovementioned aims were not met with NIV alone. If severe mask/mouth leak was not able to be controlled or the participant unable to tolerate a chin strap, then the pressures were reduced and additional O 2 was added as required. Pressures and requirement for any additional entrained oxygen were reassessed and titrated at 3-, 6and 12-month reviews. Pressure preset ventilation in the spontaneous mode was used initially, with a potential change to spontaneous/timed mode for participants unable to maintain adequate ventilation in the spontaneous mode.
The control group (low-flow oxygen therapy (LFO 2 )) received LFO 2 by nasal prongs titrated during full polysomnography to maintain SpO 2 ≥ 90% during sleep. Patients were encouraged to use therapy, NIV AE O 2 or LFO 2 , for any sleep period.
Outcome measures
Event-free survival was measured as the number of people without events cumulatively over the 12 months. Any of the following were considered as an event: (i) failure of therapy measured by the number of people with arterial partial pressure of carbon dioxide (PaCO 2 ) > 60 mm Hg, an increase in PaCO 2 > 10 mm Hg from randomization or from awake daytime to sleep ABG, or an increase in TcCO 2 > 10 mm Hg from awake to sleep or sleep rises in TcCO 2 > 10 mm Hg; (ii) lung transplantation; or (iii) death. Hospitalization episodes were recorded for all participants from 0 to 3, 3 to 6 and 6 to 12 months. Age, sex, weight and body mass index (BMI) were collected at baseline in order to describe the sample. Lung function testing, including spirometry and lung volumes by plethysmography, was performed at baseline, 3, 6 and 12 months. Forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC) and residual volume (RV) are presented as percent (%) of predicted values, and RV/total lung capacity (TLC) as a percentage of the absolute values. Lung function testing occurred during the day either prior to, or following, the sleep studies. Awake ABG were obtained with the patient seated and breathing room air (late afternoon before sleep study) at each study visit to best reflect typical daily ABG. Morning ABG were sampled while the patient was recumbent and as soon as possible after awakening to reflect sleep ABG. Compliance meters for both therapies were checked at each review.
Sleep quality was measured using the Pittsburgh Sleep Quality Inventory (PSQI), a validated self-rated questionnaire that assesses sleep quality and disturbances (range of 0-21, with higher scores indicating worse sleep quality). 18 A PSQI score of greater than 5 is considered a sensitive and specific measure of poor sleep quality. Quality of life was measured using the short form (36) health survey (SF36) (0-100), where the lower the score the greater the disability. At the inception of this study, the cystic fibrosis questionnaire (CFQ) 19 and subsequent cystic fibrosis questionnairerevised (CFQ-R), 20 were not yet validated or available for use as disease-specific quality of life questionnaires. Questionnaires were administered by a study person not involved in the clinical care of the participant or in the training/monitoring of NIV or oxygen therapy and were completed by the patient.
Statistical analysis
Sample size was calculated for PaCO 2 . A clinically relevant difference in PaCO 2 at 12 months was considered to be 2.5 mm Hg (SD 1.25). Allowing for an attrition rate of 20%, 40 patients (power of 90% and α of 5%) were required. Risk difference (95% CI) was calculated to compare event rate between groups, and mean difference (95% CI) was calculated to compare interval data between groups. Kaplan-Meier analysis was used to examine event-free survival.
RESULTS
Flow of participants throughout the study
Recruitment occurred over 12 years (June 1998 and April 2010). A total of 29 adult patients (aged 18-50 years) were randomized. Data collection was formally ceased without achieving the target sample size. Data were not prospectively gathered on numbers of patients screened, nor numbers eligible but not participating. Participant accrual is presented in Figure S1 (Supplementary Information).
Fourteen (14) participants were randomly allocated to the experimental group and 15 to the control group. Groups were similar at baseline in terms of age, sex, BMI (Table 1) as well as lung function, ABG, sleep quality and quality of life ( Table 2) .
Initial mean IPAP titrated at baseline was 13 cm H 2 O (SD 1), EPAP 5 cm H 2 O (SD 1) and only three participants in the experimental group required additional supplemental O 2 (1-2 L/min). At baseline, the participants in the control group required 1 L/min (SD 0.5), with a minimum of 0.5 L/min and a maximum of 2 L/min to maintain adequate oxygenation during sleep.
Of the 29 study participants, 18 met the criteria for 'event-free survival' and were therefore followed up for 12 months (per protocol) ( Fig. 1) . Eleven participants had a protocol-defined event during the study ( Table 3) . Nine of these 11 participants were in the control group (five participants with lung transplantation including four <3 months from randomization and one at 11 months). Two participants in the experimental group had a protocol-defined event (both underwent lung transplantation <6 months following randomization). Similar numbers of participants were listed for lung transplantation in the experimental and control groups. The control group contained seven participants listed for transplantation during this study: three were listed for transplantation prior to randomization, two within 1 month, one within 3 months and one at 11 months after randomization to this study. The experimental group contained six participants listed for transplantation: one within 1 month, one within 3 months, two within 6 months, one within 7 months and one within 8 months after randomization.
Four control group participants met the treatmentfailure criteria due to elevated PaCO 2 (3, 4 and 7 months, and between the 11th and 12th month), three from a daytime awake PaCO 2 reading and one from an elevated PaCO 2 upon awakening from sleep. No participants in the experimental group met treatment-failure criteria. One participant in the experimental group ceased using NIV AE O 2 after 107 days and continued to be followed up for event-free survival and hospitalization (no further sleep studies). TcCO 2 was measured in all participants but was often unreliable due to artefact. Although every effort was made to monitor NIV and oxygen compliance using the built-in meters, results for compliance are not presented due to missing and unreliable data. At 3 months, the NIV average use was approximately 4.3 h/night and the LFO 2 was 7.0 h/night.
Comparison of NIV AE O 2 to LFO 2
The incidence of event-free survival was 33% (95% CI: 5-58%) higher in the experimental group at 3 months and 46% (95% CI: 10-68%) higher at 12 months than the control group (Table 3, Fig. 2 ).
The experimental group had a mean 2 mm Hg (95% CI: −6 to 2) lower PaCO 2 at 3 months, 1 mm Hg (95% CI: −6 to 4) lower PaCO 2 at 6 months and 3 mm Hg (95% CI: −10 to 4) lower PaCO 2 at 12 months, although not statistically significant. With respect to PaO 2 , the experimental group had a mean 6 mm Hg (95% CI: −6 to 18) higher PaO 2 at 3 months, 4 mm Hg (95% CI: −10 to 2) lower PaO 2 at 6 months and 1 mm Hg (95% CI: −16 to 18) higher PaO 2 at 12 months, also not statistically significant (Table S1, Supplementary Information) .
Group data for other outcome measures are presented in Table 2 , and the within-group and between- group differences in Table S1 (Supplementary Information). The experimental group had a mean 0.5 (95% CI: −1.1 to 0.1) less hospital admissions per participant from 0 to 3 months, 0.1 (95% CI: −0.6 to 0.8) more admissions from 3 to 6 months and 0.1 (95% CI: −0.8 to 1.0) more admissions from 6 to 12 months, all of which were not statistically significant (Table S1 , Supplementary Information).
For the secondary outcome measures, in the participants who remained event-free at 3, 6 and 12 months, the only significant difference between the groups was in RV (% predicted) at 3 and 12 months. The experimental group had a mean 16% (95% CI: 2 to 30) greater RV % predicted at 3 months and 25% (95% CI: 0 to 50) greater RV % predicted at 12 months. There was no statistical difference between groups in PSQI or domains of the SF36, either at baseline or at 3, 6, or 12 months.
DISCUSSION
This long-term randomized trial compared NIV AE O 2 to LFO 2 in adult CF for event-free survival over a 12-month period, where events included failure of therapy (defined by worsening hypercapnia), lung transplantation or death. Participants in the NIV AE O 2 group were significantly more likely to have event-free survival at 12 months following randomization than those in the LFO 2 group, and fewer participants in the NIV AE O 2 group met the criteria for failure of therapy.
There were no differences in ABG, lung function or hospitalizations between the NIV AE O 2 and LFO 2 groups during the study. All randomized participants had evidence of sleep oxyhaemoglobin desaturation with TST minimum average SpO 2 ≤ 90%. Previous work published by our group on sleep-disordered breathing in a similar patient cohort described the oxyhaemoglobin desaturation during sleep as predominantly hypopnoeas, with a TST respiratory disturbance index (RDI) of approximately 4 events/h. 3 Whilst we titrated NIV pressures with the aim to abolish snoring, obstructive events, prevent hypopnoeas and increased TcCO 2 , importantly no differences in awake evening PaCO 2 in those participants who remained event-free at 12 months was seen. Similarly, Young et al. 13 demonstrated improvement in nocturnal hypoventilation without effect upon awake ABG or lung function over 6 weeks. Worsening hypercapnia was the criteria for failure of therapy in our study, and no participants randomized to NIV AE O 2 met these criteria whereas four participants randomized to LFO 2 developed hypercapnia. However, we still did not find a difference in awake evening PaCO 2 . A possible explanation is that our participants did not have baseline hypercapnia (mean PaCO 2 : 45 AE 3 mm Hg), and that once participants met the criteria for failure of therapy, they were considered as having an event and were removed from the trial, and so only the results from participants without hypercapnia were included. As previous studies have demonstrated that NIV is superior to LFO 2 in improving nocturnal hypoventilation, 3,13 earlier intervention with NIV may have delayed the onset of daytime hypercapnia. However, we have demonstrated no change in ABG from baseline to 12 months in those who remained event-free in both groups.
It is possible that certain subgroups of participants benefit most from NIV intervention. Ideally, large trials could stratify randomization for sex, severity of lung function and degree of sleep-disordered breathing. A retrospective study suggested patients with more severe CF lung disease and males were more likely to respond well to NIV. 8 While increasing severity of lung disease is associated with worsening daytime ABG, the trial of Young et al. which included only hypercapnic subjects also did not demonstrate an advantage for PaCO 2 with the use of NIV. 13 Given the strong evidence of the benefits of nocturnal NIV for hypercapnia due to COPD, 21 earlier uncontrolled and retrospective studies in CF [8] [9] [10] [11] [12] 22 and difficulties recruiting to randomized controlled trials in patients with advanced lung disease, further larger trials are unlikely to be undertaken.
Previous studies have demonstrated good compliance with NIV in the CF population, 13, 22, 23 although Gozal reported a preference for oxygen therapy to NIV and oxygen overnight. 24 In this current trial, only 1 out of 14 participants was unable to tolerate NIV therapy. Our study adds to previous studies supporting the feasibility of using NIV in the adult CF population. NIV has the potential to worsen the daily burden of treatment for patients with CF, due to requirements to clean and maintain equipment, as well as the potential negative psychological effects of wearing a face or nasal mask for sleeping. 25 However, encouragingly, we did not demonstrate differences between groups in measures of sleep quality or quality of life.
A target sample size of 40 was required to demonstrate a clinically relevant difference in PaCO 2 and this was not achieved. In addition, our numbers reduced over 12 months due to failure of therapy and the need for lung transplantation, further increasing the likelihood of a type II error. Changes in CF medications such as the advent of the routine use of macrolides, 26 increased clinical use of NIV in CF [8] [9] [10] [11] 22 and increased numbers of CF patients undergoing lung transplantation may have affected recruitment to this study. As no CF disease-specific questionnaire was available at the time the study commenced, we used the SF36 and the PSQI as subjective measures of sleep quality and quality of life. A strength of this study was its long-term, prospective randomized structure, the low number of dropouts and that it was the first to measure and report on event-free survival comparing NIV AE O 2 to LFO 2 . Morbidity associated with advanced lung disease remains common and, in fact for many, its duration often more prolonged now than at the time of the study adding to its generalizability to the current adult CF population. 27, 28 We have shown that NIV AE O 2 during sleep significantly increases event-free survival over 12 months in adults with CF. Although not accompanied by statistically significant differences in ABG, lung function, hospitalizations or questionnaire data, this study showing event-free survival benefit adds to the body of evidence supporting the safety, feasibility and effectiveness of the use of NIV in CF lung disease.
Data availability statement: Individual participant data collected during the trial will be available to investigators following deidentification for use in meta-analysis.
